PDCD11

Protein RRP5 homolog · Q14690 · PDCD11 on Sugi Atlas →

0 patent compounds predicted against PDCD11, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PDCD11 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma PHASE3COMPLETED
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification PHASE2/PHASE3RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Azacitidine and Pembrolizumab in Pancreatic Cancer PHASE2COMPLETED
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Immunoregulatory Therapy for 2019-nCoV PHASE2UNKNOWN
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma PHASE2ACTIVE_NOT_RECRUITING
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary PHASE2UNKNOWN
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype PHASE2ACTIVE_NOT_RECRUITING
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors PHASE1/PHASE2COMPLETED
MPDL3280A-treatment-IST-UMCG PHASE2UNKNOWN
Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab PHASE2UNKNOWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer PHASE1RECRUITING
Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 PHASE1COMPLETED
Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome PHASE1COMPLETED
Effect of Severe Trauma on PD1 and Its Legend (PD1/L1) on T Lymphocytes and Correlation With Mortality nanUNKNOWN
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies nanUNKNOWN
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) nanNOT_YET_RECRUITING
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases nanNOT_YET_RECRUITING
Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma nanCOMPLETED
Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy nanCOMPLETED
WGA in Platinum-refractory HNSCC Underwent Nivolumab nanUNKNOWN
Immune Checkpoints in Intraabdominal Ascites Fluid nanCOMPLETED
Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC nanUNKNOWN
Role of Programmed Death Ligand 1 in Colorectal Cancer nanNOT_YET_RECRUITING
Patient's Derived Organoids for Drug Screening in Glioblastoma nanNOT_YET_RECRUITING
BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer) nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PDCD11 binder may also engage these)

ProteinNameSimilarity
A7MB10 1.000 A7MB10 →
Q6NS46 0.997 Q6NS46 →
E7FDW8 0.961 E7FDW8 →
Q9BXT6 0.959 Q9BXT6 →
Q6NU04 0.959 Q6NU04 →
Q5M7P8 0.957 Q5M7P8 →
Q99MV5 0.956 Q99MV5 →
A6NAF9 0.955 A6NAF9 →
Q15061 0.954 Q15061 →
Q6ZQL4 0.954 Q6ZQL4 →
F1R237 0.953 F1R237 →
D2H0H6 0.953 D2H0H6 →
Q5BK48 0.952 Q5BK48 →
A0A1L8HX76 0.952 A0A1L8HX76 →
E2RDV1 0.952 E2RDV1 →
Q9Y4C8 0.951 Q9Y4C8 →
Q5VZ19 0.951 Q5VZ19 →
A2RV18 0.951 A2RV18 →
Q6DFC6 0.951 Q6DFC6 →
Q3V3E1 0.951 Q3V3E1 →
E1BMP7 0.950 E1BMP7 →
Q0P4R5 0.950 Q0P4R5 →
Q5RAH6 0.950 Q5RAH6 →
Q8R3C6 0.950 Q8R3C6 →
Q9R1R4 0.950 Q9R1R4 →
Q8BZW8 0.950 Q8BZW8 →
Q8K450 0.950 Q8K450 →
P47823 0.949 P47823 →
PRMT9 Protein arginine N-methyltransferase 9 0.949 landscape →
Q8K1H1 0.949 Q8K1H1 →